Grants

The Cure For Lymphoma Foundation, a nonprofit organization dedicated to funding lymphoma research, is seeking candidates for fellowship grants. The grants will provide salary support in the amount of $25,000 for 1 year. They will also provide $5,000 of additional support (including fringe benefits). Candidates must hold an M.D., Ph.D., D.D.S., or D.V.M. degree and must have completed at least 2 years of postdoctoral research. Their research should address important translational or clinical questions relevant to the etiology or treatment of lymphoma. Only one candidate may be proposed by a sponsor who will supervise the candidate’s research.

The grant application deadline is November 1, 1996. Grants will be announced in February 1997 and will begin July 1, 1997. Grant applications will be reviewed by the Scientific Advisory Board, chaired by Dr. Joseph Bertino. Other members include Dr. James Armitage, Dr. George Canellos, Dr. Charles Cushman, Dr. Vincent DeVita, Dr. David Gore, Dr. William Hrynuk, Dr. Stanley Korsmeyer, Dr. Saul Rosenberg, and Dr. John Ultmann.

For applications and further information, contact: Cure For Lymphoma Foundation, 1 Dag Hammarskjold Plaza, New York, NY 10017 (telephone: 212-319-5857, fax: 212-758-8950).

Employment

Chairman, Department of Medicine

Memorial Sloan-Kettering Cancer Center (MSKCC) is seeking a Chairman of its Department of Medicine. MSKCC is the largest and oldest comprehensive cancer center in the United States. It is academically affiliated with Cornell University Medical College and is one of its primary teaching hospitals. The Department of Medicine has a commitment to patient care, teaching, and clinical research in cancer and related areas. We welcome applications from experienced academic physicians who can provide direction and vision for programs of patient care, clinical investigation, and training of fellows. The individual selected will be in a unique position to participate in the leadership of this major cancer center and biomedical research institution. Please send curriculum vitae and bibliography to: Zvi Fuchs, M.D., Chairman, Search Committee, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. MSKCC is an equal opportunity/affirmative action employer.

Medical Oncologist-Assistant Professor of Medicine

The Department of Gastrointestinal Oncology & Digestive Diseases, The University of Texas M. D. Anderson Cancer Center (UTMDACC) is seeking a board-certified or board-eligible medical oncologist with clinical expertise in patient care and management of patients with malignancies of the gastrointestinal tract. Candidates should demonstrate capability for active participation in development and conduct of clinical trials and translational research related to gastrointestinal cancers. UTMDACC is an equal opportunity employer. Women and minority candidates are encouraged to apply. Interested applicants should send a letter and curriculum vitae to James L. Abbruzzese, M.D., Chairman, Department of G.I. Oncology & Digestive Diseases, Box 78, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.

Gastroenterologist-Assistant/Associate Professor of Medicine

The Department of Gastrointestinal Oncology & Digestive Diseases, The University of Texas M. D. Anderson Cancer Center (UTMDACC) is seeking a board-certified or board-eligible gastroenterologist with clinical and academic expertise in interventionnal endoscopy. Active participation in development and conduct of endoscopic clinical trials and research in gastrointestinal cancers with strong interests in teaching and proven investigative abilities are desired. UTMDACC is an equal opportunity employer. Women and minority candidates are encouraged to apply. Interested applicants should send a letter and curriculum vitae to: James L. Abbruzzese, M.D., Chairman, Department of G.I. Oncology & Digestive Diseases, Box 78, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.

Tenure-Level/Tenure-Track Investigator

The National Cancer Institute’s Metabolism Branch is conducting a search for a tenure-level or tenure-track investigator to initiate independent research that applies the techniques of modern molecular genetics to clinically relevant issues with a special focus on cancer or immunodeficiency. For more than three decades, the Metabolism Branch, headed by Thomas A. Waldmann, M.D., has been an exemplar of patient-oriented clinical research in the fields of immunology and oncology using approaches that extend from fundamental molecular genetics applied to the regulation of gene expression to carefully controlled clinical trials. Areas of special interest that have been brought to practical application include somatic gene therapy for cancer and immunodeficiency diseases, antigen processing and presentation to T lymphocytes with applications to vaccine design for AIDS and cancer, and the development of novel cytokine receptor-directed therapies for the treatment of cancer, especially those approaches using humanized monoclonal antibodies armed with radionuclides.

We are seeking an imaginative and ambitious individual who is capable of establishing a vigorous, internationally recognized, independent research program. The applicant should have a strong record of achievement in translational clinical research or in molecular genetics with relevance to human cancer or immunodeficiency. The successful candidate will have broad latitude in determining particular research directions. Areas of special interest that are related to the branch, however, focus on oncology and immunology and include angiogenesis, apoptosis, cell cycle control, stem cell biology, gene isolation and identification, as well as gene transfer for therapy of human disease.

Applicants should send a detailed description of research plans, curriculum vitae, selected publications, and the names of three references to: Ira Pastan, M.D., Chair, Search Committee, Bldg. 10, Rm. 4N115, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892-1374 (fax: 301-496-9956). To ensure full consideration, applications should arrive by September 3, 1996. The National Cancer Institute is an equal opportunity employer. Selection for this position will be based solely on merit, with no discrimination for nonmerit reasons such as race, color, religion, gender, national origin, politics, marital status, physical or mental disability, age, sexual orientation, or membership or nonmembership in an employee organization.

Director of Health Content

The American Cancer Society is creating a new business unit to fill the rapidly growing demand for cancer information. The organization is seeking a Director of Health Content to lead the development of this information.

Responsibilities include directing the development and acquisition of cancer information from sources both inside and outside the organization, growing and maintaining a medically and scientifically sound, wide, and deep database of cancer information, and providing editorial management for a variety of health content products. In addition, the director manages the selection, activities, and functions of a prestigious group of oncology professionals serving as the editorial board for the database and other content products.

Reporting to the General Manager of Health Content Products, this position requires a doctoral degree in medicine and a minimum of 10 years’ experience. A thorough knowledge of cancer medicine is essential. Clinical cancer practice experience is desirable. The successful candidate will possess excellent medical writing, editing, and publishing skills. A high level of comfort in a computerized environment, including a working knowledge of Web medical content, is required. An entrepreneurial approach is highly desirable. Please send curriculum vitae in strict confidence to: Harry Johns, General Manager of Health Content Products, American Cancer Society, Inc., 1599 Clifton Rd., N.E., Atlanta, GA 30329-4251. E.O.E. M/F/D/V.

Clinical Trial

*Phase II/III Trial

Neurex Corporation, Menlo Park, Calif., has initiated its phase II/III clinical trial with SXN-111 to evaluate safety and efficacy in the treatment of severe and intractable pain in patients with cancer or AIDS. The double-blinded, crossover study, which includes a long-term treatment phase, will target 200 patients in over 30 centers in the United States. Initial results released in May 1995, and subsequently reported at the American Pain Society conference in November, demonstrated significant reductions in pain for these very difficult to treat patients.

The SNX-111 clinical trial is being conducted in the following cities: Atlanta, GA; Baltimore, MD; Beverly Hills, CA; Camden, NJ; Chicago, IL; Cleveland, OH; Houston, TX; Huntsville, AL; Iowa City, IA; Kansas City, MO; Lexington, KY; Marshfield, WI; Mobile, AL; Northport, AL; Portland, OR; San Diego, CA; San Francisco, CA; Seattle, WA; Springfield, IL; and Warrenville, OH. Patients interested in participation may visit Clinical Solutions information site on the Internet at http://www.41mad.com/elsolutions or call 1-800-57-STUDY, ext. 96.